Payment overview · 2025
General Payments
$508.44
6 reported records · 4 companies
Healthcare provider profile · identity verified
Frederick R. Yarid, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MORRISTOWN, TN · NPI 1508865205
Verified facts
What the public records show
CMS Open Payments records show Frederick R. Yarid, M.D. received $508.44 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 45.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.37 | 45.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $149.70 | 29.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $110.33 | 21.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.04 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $508.44 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $230.37 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $110.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $101.42 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.28 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 251 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 55 |
| Gabapentin | Gabapentin | 195 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 169 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 154 | 47 |
| Lisinopril | Lisinopril | 141 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 45 |
| Omeprazole | Omeprazole | 121 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 34 |
| Metformin Hcl | Metformin Hcl | 105 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 104 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 32 |
| Losartan Potassium | Losartan Potassium | 98 | 32 |
| Tramadol Hcl | Tramadol Hcl | 95 | 22 |
| Trazodone Hcl | Trazodone Hcl | 86 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 28 |
| Lorazepam | Lorazepam | 80 | 20 |
| Simvastatin | Simvastatin | 79 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 26 |
| Carvedilol | Carvedilol | 75 | 23 |
| Montelukast Sodium | Montelukast Sodium | 66 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 14 |
| Ozempic | Semaglutide | 60 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 19 |
| Famotidine | Famotidine | 56 | 15 |
| Allopurinol | Allopurinol | 54 | 18 |
| Jardiance | Empagliflozin | 54 | 13 |
| Benazepril Hcl | Benazepril Hcl | 48 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 15 |
| Eliquis | Apixaban | 44 | 11 |
| Glipizide Er | Glipizide | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Azithromycin | Azithromycin | 43 | 39 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Kerendia | Finerenone | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | 11 |
| Atenolol | Atenolol | 40 | 11 |
| Furosemide | Furosemide | 40 | 15 |
| Celecoxib | Celecoxib | 39 | 15 |
| Farxiga | Dapagliflozin Propanediol | 39 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 16 |
| Meloxicam | Meloxicam | 39 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 12 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 18 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 15 |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 33 | 12 |
| Potassium Chloride | Potassium Chloride | 33 | 11 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Prednisone | Prednisone | 30 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 11 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 17 |
| Baclofen | Baclofen | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Febuxostat | Febuxostat | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Cephalexin | Cephalexin | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $508.44 · 6 records | Novo Nordisk Inc | AIRSUPRA, FARXIGA, Kerendia, Ozempic, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error